What's new — Chronic kidney disease¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 7 |
| last 2 months | 15 |
| last 3 months | 17 |
| last 6 months | 29 |
| last year | 49 |
| older than a year | 280 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-09 | A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted — J Am Soc Nephrol ([PMID 42853614](https://pubmed.ncbi.nlm.nih.gov/42853614/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-02 | Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial — J Am Soc Nephrol ([PMID 42925875](https://pubmed.ncbi.nlm.nih.gov/42925875/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease, sglt2-inhibitors |
| 2026-10-02 | Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial — N Engl J Med ([PMID 42912700](https://pubmed.ncbi.nlm.nih.gov/42912700/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-10-02 | Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy — N Engl J Med ([PMID 42912669](https://pubmed.ncbi.nlm.nih.gov/42912669/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-10-02 | Video Decision Support and Advance Care Planning in Older Adults With Advanced Kidney Disease: The VIDEO-KD Randomized Clinical Trial — JAMA Intern Med ([PMID 42911803](https://pubmed.ncbi.nlm.nih.gov/42911803/){target="_blank" rel="noopener"}) | conservative-and-supportive-care |
| 2026-10-02 | Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis — N Engl J Med ([PMID 42911185](https://pubmed.ncbi.nlm.nih.gov/42911185/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-10-02 | Atacicept in IgA Nephropathy - Phase 3 Trial Final Efficacy Analysis — N Engl J Med ([PMID 42911181](https://pubmed.ncbi.nlm.nih.gov/42911181/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-10-01 | Validation of the Klinrisk CKD Progression Model in the Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) Population — Kidney360 ([PMID 42868053](https://pubmed.ncbi.nlm.nih.gov/42868053/){target="_blank" rel="noopener"}) | risk-prediction-and-prognosis |
| 2026-10-01 | Haemodiafiltration, haemofiltration and haemodialysis for adults with kidney failure — Cochrane Database Syst Rev ([PMID 42867023](https://pubmed.ncbi.nlm.nih.gov/42867023/){target="_blank" rel="noopener"}) | kidney-replacement-therapy-decisions |
| 2026-10-01 | Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial — Nat Med ([PMID 42823485](https://pubmed.ncbi.nlm.nih.gov/42823485/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glp1-and-emerging-therapy, pathophysiology-and-progression |
| 2026-09-03 | An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression — Kidney Int ([PMID 42815853](https://pubmed.ncbi.nlm.nih.gov/42815853/){target="_blank" rel="noopener"}) | definition-staging-and-measurement |
| 2026-09-02 | Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria — Kidney Int ([PMID 42778148](https://pubmed.ncbi.nlm.nih.gov/42778148/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mineralocorticoid-receptor-antagonists |
| 2026-09-01 | Initial Changes in eGFR During Treatment with Balcinrenone and Dapagliflozin: An Exploratory Analysis of the MIRO-CKD Trial — Clin J Am Soc Nephrol ([PMID 42752537](https://pubmed.ncbi.nlm.nih.gov/42752537/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mineralocorticoid-receptor-antagonists |
| 2026-09-01 | Women's Kidney Health in Focus: A Scientific Statement From the American Heart Association — Circulation ([PMID 42751780](https://pubmed.ncbi.nlm.nih.gov/42751780/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-01 | Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline — Ann Intern Med ([PMID 42735412](https://pubmed.ncbi.nlm.nih.gov/42735412/){target="_blank" rel="noopener"}) | anaemia-of-ckd, guidelines |
| 2026-08-07 | Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis — Lancet Diabetes Endocrinol ([PMID 42567173](https://pubmed.ncbi.nlm.nih.gov/42567173/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glp1-and-emerging-therapy |
| 2026-08-02 | Liberal Fruit and Vegetable Intake in Patients With Advanced Chronic Kidney Disease With or Without Sodium Zirconium Cyclosilicate — J Ren Nutr ([PMID 42636918](https://pubmed.ncbi.nlm.nih.gov/42636918/){target="_blank" rel="noopener"}) | diet-and-nutrition |
| 2026-08-01 | Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation — JAMA Intern Med ([PMID 42329639](https://pubmed.ncbi.nlm.nih.gov/42329639/){target="_blank" rel="noopener"}) | race-and-the-egfr-equation |
| 2026-07-31 | KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP) — Nephrol Dial Transplant ([PMID 41604211](https://pubmed.ncbi.nlm.nih.gov/41604211/){target="_blank" rel="noopener"}) | anaemia-of-ckd |
| 2026-07-21 | Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial — JAMA ([PMID 42246414](https://pubmed.ncbi.nlm.nih.gov/42246414/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — J Am Coll Cardiol ([PMID 42265997](https://pubmed.ncbi.nlm.nih.gov/42265997/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-05 | Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) — Lancet ([PMID 42248158](https://pubmed.ncbi.nlm.nih.gov/42248158/){target="_blank" rel="noopener"}) | guidelines, mineralocorticoid-receptor-antagonists |
| 2026-06-04 | Finerenone in Persons with Chronic Kidney Disease without Diabetes — N Engl J Med ([PMID 42246672](https://pubmed.ncbi.nlm.nih.gov/42246672/){target="_blank" rel="noopener"}) | clinical-trials-landscape, diabetic-kidney-disease, guidelines, mineralocorticoid-receptor-antagonists |
| 2026-06-04 | Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial — Lancet ([PMID 42242268](https://pubmed.ncbi.nlm.nih.gov/42242268/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glp1-and-emerging-therapy, inherited-and-glomerular-disease |
| 2026-06-01 | Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study — BMJ Open ([PMID 42315275](https://pubmed.ncbi.nlm.nih.gov/42315275/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2026-05-14 | Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial — N Engl J Med ([PMID 42127391](https://pubmed.ncbi.nlm.nih.gov/42127391/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-05-08 | The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial — Transplantation ([PMID 42102257](https://pubmed.ncbi.nlm.nih.gov/42102257/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2026-05-05 | Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals — Nat Med ([PMID 42086979](https://pubmed.ncbi.nlm.nih.gov/42086979/){target="_blank" rel="noopener"}) | guidelines, risk-prediction-and-prognosis |
| 2026-05-01 | A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial — Lancet Diabetes Endocrinol ([PMID 42114520](https://pubmed.ncbi.nlm.nih.gov/42114520/){target="_blank" rel="noopener"}) | glp1-and-emerging-therapy |
| 2026-04-25 | Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis — Lancet ([PMID 42035778](https://pubmed.ncbi.nlm.nih.gov/42035778/){target="_blank" rel="noopener"}) | ras-blockade-and-blood-pressure |
| 2026-04-08 | Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial — J Am Soc Nephrol ([PMID 41949916](https://pubmed.ncbi.nlm.nih.gov/41949916/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-04-02 | Clinical and histologic predictors of non-diabetic kidney disease in patients with diabetes mellitus — Kidney Int ([PMID 42034202](https://pubmed.ncbi.nlm.nih.gov/42034202/){target="_blank" rel="noopener"}) | diabetic-kidney-disease |
| 2026-03-05 | Finerenone in Type 1 Diabetes and Chronic Kidney Disease — N Engl J Med ([PMID 41780000](https://pubmed.ncbi.nlm.nih.gov/41780000/){target="_blank" rel="noopener"}) | clinical-trials-landscape, diabetic-kidney-disease, guidelines, mineralocorticoid-receptor-antagonists |
| 2026-03-02 | Iptacopan in IgA Nephropathy - Final 24-Month Data — N Engl J Med ([PMID 41910396](https://pubmed.ncbi.nlm.nih.gov/41910396/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-03-02 | Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary — Kidney Int ([PMID 41895685](https://pubmed.ncbi.nlm.nih.gov/41895685/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-20 | Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis — JAMA ([PMID 41202026](https://pubmed.ncbi.nlm.nih.gov/41202026/){target="_blank" rel="noopener"}) | overview, sglt2-inhibitors |
| 2026-01-09 | Chronic Kidney Disease and Superimposed Acute Kidney Injury: Greater Impact of Acute Insults on Outcomes — Int J Nephrol ([PMID 41523706](https://pubmed.ncbi.nlm.nih.gov/41523706/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-01-01 | Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) — Kidney Int ([PMID 41485807](https://pubmed.ncbi.nlm.nih.gov/41485807/){target="_blank" rel="noopener"}) | anaemia-of-ckd, guidelines |
| 2026-01-01 | Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction — JAMA Cardiol ([PMID 41369941](https://pubmed.ncbi.nlm.nih.gov/41369941/){target="_blank" rel="noopener"}) | mineralocorticoid-receptor-antagonists |
| 2026-01-01 | 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358881](https://pubmed.ncbi.nlm.nih.gov/41358881/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-01 | Chronic Kidney Disease Prevalence and Awareness Among US Adults — JAMA Cardiol ([PMID 41205219](https://pubmed.ncbi.nlm.nih.gov/41205219/){target="_blank" rel="noopener"}) | causes-and-aetiology, definition-staging-and-measurement, epidemiology-and-burden, guidelines, overview, pathophysiology-and-progression, race-and-the-egfr-equation, risk-prediction-and-prognosis |
| 2025-12-09 | Conservative kidney management versus dialysis for stage 5 chronic kidney disease in older people — Cochrane Database Syst Rev ([PMID 41363177](https://pubmed.ncbi.nlm.nih.gov/41363177/){target="_blank" rel="noopener"}) | conservative-and-supportive-care, kidney-replacement-therapy-decisions, symptom-burden-and-patient-experience |
| 2025-12-02 | Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis — JAMA ([PMID 41202182](https://pubmed.ncbi.nlm.nih.gov/41202182/){target="_blank" rel="noopener"}) | definition-staging-and-measurement |
| 2025-12-01 | Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial — Clin J Am Soc Nephrol ([PMID 41385300](https://pubmed.ncbi.nlm.nih.gov/41385300/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2025-11-08 | Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial — Lancet ([PMID 41218621](https://pubmed.ncbi.nlm.nih.gov/41218621/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mineralocorticoid-receptor-antagonists |
| 2025-11-07 | Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial — J Am Coll Cardiol ([PMID 41493296](https://pubmed.ncbi.nlm.nih.gov/41493296/){target="_blank" rel="noopener"}) | diabetic-kidney-disease, mineralocorticoid-receptor-antagonists, potassium-acidosis-and-metabolic |
| 2025-11-07 | Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet ([PMID 41213283](https://pubmed.ncbi.nlm.nih.gov/41213283/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview |
| 2025-11-06 | A meta-analysis of albuminuria as a surrogate endpoint for kidney failure — Nat Med ([PMID 41198855](https://pubmed.ncbi.nlm.nih.gov/41198855/){target="_blank" rel="noopener"}) | definition-staging-and-measurement, inherited-and-glomerular-disease, overview |
Trials — what has moved¶
52 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 4 |
| trial records updated in the last month | 13 |
| trial records updated in the last 2 months | 21 |
| trial records updated in the last 3 months | 23 |
| trial records updated in the last 6 months | 31 |
| trial records updated in the last year | 40 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | A Study to Learn How Well the Study Treatment Finerenone Works and How | PHASE3 | 242 | Change in UACR From Baseline (Ratio to Baseline) Over 6 Months | 28 | 13 | 2 |
| 2026-10-01 | Atacicept in Subjects With IgA Nephropathy | PHASE3 | 428 | Percentage Change From Baseline in Urine Protein to Creatinine Ratio ( | 12 | 115 | 0 |
| 2026-07-13 | A Study to Learn How Well the Treatment Combination of Finerenone and | PHASE2 | 1664 | Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) | 52 | 406 | 6 |
| 2026-06-26 | Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compar | PHASE2 | 324 | Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Basel | 17 | 30 | 0 |
| 2026-06-03 | Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotr | PHASE2 | 60 | Placebo-adjusted Change From Baseline in Automated Office Blood Pressu | 2 | 47 | 0 |
| 2026-01-14 | A Research Study to Find Out How Semaglutide Works in the Kidneys Comp | PHASE3 | 106 | Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Depende | 19 | 26 | 3 |
| 2025-03-20 | A Research Study to See How Semaglutide Works Compared to Placebo in P | PHASE3 | 3533 | Number of Participants From Time of Randomization to First Occurrence | 1827 | 1029 | 506 |
| 2024-12-03 | Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglo | PHASE3 | 365 | Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months | 27 | 177 | 1 |
| 2024-07-03 | A Study of the Effect and Safety of Sparsentan in the Treatment of Pat | PHASE3 | 406 | Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at | 146 | 364 | 1 |
| 2023-07-27 | EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empaglifloz | PHASE3 | 6609 | Interventional Part: Time to First Occurrence of Kidney Disease Progre | 2256 | 490 | 667 |
| 2022-04-15 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mel | PHASE3 | 7352 | The First Occurrence of the Composite Endpoint of Cardiovascular Death | 2373 | 3514 | 722 |
| 2021-07-19 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mel | PHASE3 | 5734 | The First Occurrence of the Composite Endpoint of Onset of Kidney Fail | 1873 | 3186 | 472 |
| 2021-07-07 | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and | PHASE3 | 4304 | Time to the First Occurrence of Any of the Components of the Composite | 1362 | 979 | 266 |
| 2019-11-20 | Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular | PHASE3 | 4401 | Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End | 1543 | 2767 | 357 |
35 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.